Validation of novel imaging methodologies for use as cancer clinical trial end-points
- 17 December 2008
- journal article
- research article
- Published by Elsevier in European Journal Of Cancer
- Vol. 45 (2) , 290-299
- https://doi.org/10.1016/j.ejca.2008.10.030
Abstract
No abstract availableKeywords
This publication has 44 references indexed in Scilit:
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal Of Cancer, 2009
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Response-Independent Survival Benefit in Metastatic Colorectal Cancer: A Comparative Analysis of N9741 and AVF2107Journal of Clinical Oncology, 2008
- We Should Desist Using RECIST, at Least in GISTJournal of Clinical Oncology, 2007
- DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agentsBritish Journal of Cancer, 2007
- The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiformeNeuro-Oncology, 2007
- Measures of Response: RECIST, WHO, and New AlternativesJournal of Clinical Oncology, 2006
- Phase II Studies of Modern Drugs Directed Against New Targets: If You Are Fazed, Too, Then Resist RECISTJournal of Clinical Oncology, 2004
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendationsEuropean Journal Of Cancer, 1999